Showing 1 - 13 results of 13 for search 'Zhigang Peng', query time: 0.02s
Refine Results
-
1
-
2
-
3
Global Nuclear Explosion Discrimination Using a Convolutional Neural Network by Louisa Barama, Jesse Williams, Andrew V. Newman, Zhigang Peng
Published 2023-09-01Get full text
Article -
4
A Feasible Method of Angiogenesis Assessment in Gastric Cancer Using 3D Microvessel Density by Lu Zhang, Fei Zheng, Zhigang Peng, Zijing Hu, Zhi Yang
Published 2018-01-01Get full text
Article -
5
-
6
-
7
Subsurface structure and impact process of Yilan Crater, northeastern China by Yangfan Deng, Samuel Bignardi, Zhou Zhang, Zhigang Peng, Cheng Xiong, Sheng Zhu, Jixiao Ma, Mianshui Rong, Ming Chen
Published 2025-04-01Get full text
Article -
8
-
9
-
10
A multicenter, open-label, single-arm, phase Ib clinical trial of HH2853 treatment in patients with relapsed and/or refractory peripheral T-cell lymphoma by Huangming Hong, Zegeng Chen, Mingzhi Zhang, Zhigang Peng, Jianzhen Shen, Yuerong Shuang, Hui Zhou, Hongqiang Guo, He Huang, Fei Li, Zhengzi Qian, Lihong Liu, Liang Wang, Wei Yang, Liling Zhang, Pengcheng He, Shen Qian, Fugen Li, Meng Li, Tongyu Lin
Published 2025-04-01Get full text
Article -
11
Tifcemalimab as monotherapy or in combination with toripalimab in patients with relapsed/refractory lymphoma: a Phase I trial by Yuqin Song, Jun Ma, Huilai Zhang, Yan Xie, Zhigang Peng, Yuerong Shuang, Fei Li, Yufu Li, Haiyan Yang, Liqun Zou, Xiuhua Sun, Weili Zhao, Wenrong Huang, Yunhong Huang, Hui Zhou, Yifan Wang, Weiwei Wang, Jing Xu, Rong Deng, Qin Meng, Jun Zhu
Published 2025-05-01Get full text
Article -
12
Clinical characteristics, treatment patterns, and survival outcomes of 1031 patients with peripheral T cell lymphoma in china: a multicenter, real-world study by Ling Huang, Yong Yang, Zhenyu Zhao, Shengsheng Zhou, Jingsong Wu, Ning Wang, Fen Zhang, Keqian Shi, ChengPing Li, Xiaolei Wei, Hongyu Zhang, Yun Lin, Guowei Li, Hui Zhou, Hanguo Guo, Xinmiao Jiang, Xiaojuan Wei, Feili Chen, Sichu Liu, Caidi Lin, Zhanli Liang, Yilan Huang, Lu Pan, Hui Yang, Yirong Jiang, Yudan Wu, Shuqin Cheng, Huifang Yang, Xiaoqiang Zheng, Xinggui Chen, Xiaoliang Li, GuiNian Huang, Jihao Zhou, Zhigang Peng, Li-e Lin, Tingbo Liu, Wenyu Li
Published 2025-07-01Get full text
Article -
13
Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial by Chuanhua Zhao, Yanqiao Zhang, Gang Wang, Jinfang Zheng, Weiqing Chen, Zheng Lu, Li Zhuang, Shanzhi Gu, Lei Han, Zhendong Zheng, Zujiang Yu, Yongsheng Yang, Hongmei Sun, Xiaoyong Wei, Ying Cheng, Hailan Lin, Bo Zhu, Guicheng Wu, Kaijian Lei, Wei Wang, Yuwen Wang, Kehe Chen, Ximing Xu, Cuiping Zheng, Yanzhi Bi, Sijuan Ding, Jingdong Zhang, Wei Li, Hailong Liu, Jun Wang, Xianling Liu, Yangfeng Du, Lianming Cai, Jingran Wang, Zhanxiong Luo, Baocai Xing, Jie Shen, Lin Yang, Jianbing Wu, Ou Jiang, Zhigang Peng, Xiuli Liu, Bangwei Cao, Liangfang Shen, Aibing Xu, Aimin Li, Shaojun Chen, Ting Fu, Jian Chen, Chuan Jin, Lei Zhang, Jun Lv, Chengwu Zhang, Xiaoman Zhang, Yu Wang, Huo Su, Qiang Zhou, Wenlin Gai, Liangzhi Xie, Jianming Xu
Published 2025-08-01Get full text
Article